NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

RecruitingPhase 1

Sponsor: Deciphera Pharmaceuticals, LLC

Conditions: Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer

Interventions: DCC-2812

Countries: United States

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Key Inclusion Criteria:

* Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
* Able to take oral medication
* If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
* Adequate organ function and electrolytes

Key Exclusion Criteria:

* Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
* Impaired cardiac function
* Major surgery within 28 days of the first dose of study drug

Locations (8)

Boston, Massachusetts, United States
Ann Arbor, Michigan, United States
St Louis, Missouri, United States
Cleveland, Ohio, United States
Philadelphia, Pennsylvania, United States
Nashville, Tennessee, United States
Austin, Texas, United States
San Antonio, Texas, United States